Curcumin-loaded polymeric nanoparticles for neuroprotection in neonatal rats with hypoxic-ischemic encephalopathy

Improvement of Curcumin Bioavailability for Medical Applications

“…The curcumin nanoparticle size was approximately 60 nm with a capacity of curcumin loading of 5.3 and 6% for curcumin-PLGA NPs and curcumin-PLGA-PEG NPs, respectively. An initial in vitro burst release was observed at 4 h for both curcumin-PLGA NPs and curcumin-PLGA-PEG NPs with 40 and 49% curcumin release, respectively, followed by sustained drug release of up to 59 and 99% at 4 h. Moreover, an in vivo study in rats showed that PLGA-PEG NPs increased curcumin diffusion through the brain parenchyma more highly than PLGA NPs and that curcumin PLGA-PEG NPs showed greater absorption at the site of injury [123]. In addition, curcumin-loaded poly (ethylene glycol)-poly (lactic acid) (PEG-PLA) nanospheres (cur-PEG-PLA NS) were prepared by the simple emulsion method.…”

Curcumin’s Nanomedicine Formulations for Therapeutic Application in Neurological Diseases

“…Moreover, the surface coatings with PEG blocks have been shown to increase colloidal stability, solubility as well as to improve polymeric nanoparticle diffusion in brain tissues [191,192]. Recently, the in vivo investigation of CUR-loaded PLGA-PEG micellar nanocarriers evidenced an increase of the relevant pharmacokinetic parameters [193]. More specifically, the CUR-loaded nanocarriers could overcome the impaired BBB, efficiently diffuse through the brain parenchyma, and deliver a protective effect in the regions of injured neonatal rats'brains (with hypoxic-ischemic encephalopathy) [193].…”

“…Recently, the in vivo investigation of CUR-loaded PLGA-PEG micellar nanocarriers evidenced an increase of the relevant pharmacokinetic parameters [193]. More specifically, the CUR-loaded nanocarriers could overcome the impaired BBB, efficiently diffuse through the brain parenchyma, and deliver a protective effect in the regions of injured neonatal rats'brains (with hypoxic-ischemic encephalopathy) [193]. Moreover, micelles formed by synthetic PLGA-PEG-PLGA triblock copolymers have been revealed to be able to modifyCUR pharmacokinetics and tissue distribution [194].…”

Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury

“…For instance, a polyamidoamine dendrimer has been used to successfully deliver n-acetylcysteine to reduce brain injury in a rabbit model of cerebral palsy induced by hypoxia/ischemia (231,232). In addition, a poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) nanoparticle has successfully increased the delivery of the histone deacetylase inhibitor, curcumin, to the brain in a model of term infant NE related to HI (233). An interesting biomaterials approach involves the engineering of nanoparticles to release their "cargo" in response to tissue damage-in this case-in response to acidosis in the brain subsequent to ischemia (234).…”